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Background
The evaluation of treatments for rare diseases presents a
number of challenges for trial practitioners, regulators
and policy makers. Small sample sizes mean that ‘stan-
dard’ approaches to trial design and analysis may not be
appropriate and alternatives such as Bayesian trial
designs have been recommended [Lilford et al 1995].
However, little is known about the design and analysis
approaches that have been implemented in practice.
Methods
We will perform a review of rare disease clinical trials to
(i) describe the trial design characteristics that have
been applied to rare disease clinical trials;
(ii) summarise the characteristics that facilitate or hin-
der the design, conduct and publication of rare disease
clinical trials;
(iii) summarise approaches in which researchers have
attempted to improve the efficiency of rare disease clini-
cal trials;
(iv) identify whether alternative design and analysis
considerations may have been possible in a given trial.
Rare disease clinical trials will be identified through elec-
tronic search of trial registries (http://www.clinicaltrials.
gov and http://www.orpha.net). Trials will be assessed for
inclusion by two independent reviewers and relevant data
extracted. Trials will be summarised qualitatively with
regard to the methodologies adopted and their strengths
and weaknesses.
Results
Preliminary results will be available to discuss at the
conference.
Conclusions
The purpose of this review is to explore how rare dis-
ease trials have been implemented. This will provide a
much needed summary of approaches that have been
used in practice, highlighting where possible, why parti-
cular designs have been chosen.
Authors’ details
1University of Liverpool, Liverpool, UK. 2Roche Products Limited, Welwyn
Garden City, UK. 3Lancaster University, Lancaster, UK. 4Birmingham University,
Birmingham, UK.
Published: 29 November 2013
doi:10.1186/1745-6215-14-S1-P34
Cite this article as: Bell et al.: Clinical trials in rare diseases: a review of
practice. Trials 2013 14(Suppl 1):P34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1University of Liverpool, Liverpool, UK
Full list of author information is available at the end of the article
Bell et al. Trials 2013, 14(Suppl 1):P34
http://www.trialsjournal.com/content/14/S1/P34 TRIALS
© 2013 Bell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
